JP2014523238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523238A5 JP2014523238A5 JP2014515209A JP2014515209A JP2014523238A5 JP 2014523238 A5 JP2014523238 A5 JP 2014523238A5 JP 2014515209 A JP2014515209 A JP 2014515209A JP 2014515209 A JP2014515209 A JP 2014515209A JP 2014523238 A5 JP2014523238 A5 JP 2014523238A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion protein
- modified
- ubiquitin
- sequence number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims 21
- 102000037865 fusion proteins Human genes 0.000 claims 21
- 102000044159 Ubiquitin Human genes 0.000 claims 20
- 108090000848 Ubiquitin Proteins 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 239000000178 monomer Substances 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000008300 Mutant Proteins Human genes 0.000 claims 2
- 108010021466 Mutant Proteins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 102000035118 modified proteins Human genes 0.000 claims 1
- 108091005573 modified proteins Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2011/002962 | 2011-06-15 | ||
| PCT/EP2011/002962 WO2012171541A1 (en) | 2011-06-15 | 2011-06-15 | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
| PCT/EP2012/061459 WO2012172058A1 (en) | 2011-06-15 | 2012-06-15 | Human fusion proteins comprising interferons and targeted modified ubiquitin proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014523238A JP2014523238A (ja) | 2014-09-11 |
| JP2014523238A5 true JP2014523238A5 (https=) | 2015-03-26 |
Family
ID=46354263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014515209A Pending JP2014523238A (ja) | 2011-06-15 | 2012-06-15 | インターフェロンと標的化修飾ユビキチンタンパク質とを含むヒト融合タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140219959A1 (https=) |
| JP (1) | JP2014523238A (https=) |
| AU (1) | AU2012268973A1 (https=) |
| CA (1) | CA2837875A1 (https=) |
| IL (1) | IL229723A0 (https=) |
| WO (2) | WO2012171541A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2837804C (en) | 2011-06-15 | 2018-03-20 | Scil Proteins Gmbh | Dimeric binding proteins based on modified ubiquitins |
| WO2014094799A1 (en) * | 2012-12-19 | 2014-06-26 | Scil-Proteins-Gmbh | Ubiquitin moieties as a means for prolonging serum half-life |
| JP6738340B2 (ja) | 2015-02-06 | 2020-08-12 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | 新規なｅｇｆｒ結合タンパク質 |
| JP6856938B2 (ja) | 2015-07-16 | 2021-04-14 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | 新規な免疫グロブリン結合タンパク質およびアフィニティ精製におけるそれらの使用 |
| WO2017013136A1 (en) | 2015-07-20 | 2017-01-26 | Scil Proteins Gmbh | Novel binding proteins based on di-ubiquitin muteins and methods for generation |
| US11813336B2 (en) | 2016-05-04 | 2023-11-14 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
| CN109963864B (zh) | 2016-08-11 | 2024-01-02 | 瑞普利金公司 | 用于亲和色谱的碱性稳定性fc结合蛋白 |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| US11414466B2 (en) | 2017-11-07 | 2022-08-16 | Navigo Proteins Gmbh | Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer |
| MX2020007077A (es) | 2018-01-04 | 2020-10-28 | Iconic Therapeutics Inc | Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados. |
| US20200339639A1 (en) * | 2018-01-11 | 2020-10-29 | Uti Limited Partnership | Treatment of fragile x syndrome |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| MX2021007283A (es) | 2018-12-18 | 2021-07-15 | Navigo Proteins Gmbh | Proteinas de union especificas del folr1 novedosas para diagnostico y tratamiento del cancer. |
| CA3136229A1 (en) * | 2019-04-10 | 2020-10-15 | Navigo Proteins Gmbh | Novel psma specific binding proteins for cancer diagnosis and treatment |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| WO2021212220A1 (en) * | 2020-04-20 | 2021-10-28 | Altum Pharmaceuticals Inc. | Recombinant interferon |
| WO2021217113A1 (en) * | 2020-04-25 | 2021-10-28 | East Carolina University | Compositions and methods of treating a coronavirus infection by use of an interferon fusion protein |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| US20240190935A1 (en) * | 2021-04-26 | 2024-06-13 | East Carolina University | Compositions and methods of treating pathogenic infections by using fusion proteins |
| WO2023239213A1 (ko) * | 2022-06-10 | 2023-12-14 | 주식회사 쎌트로이 | 염증세포에서 특이적으로 작동하는 융합단백질 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| JP2003524018A (ja) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
| AU2001239470A1 (en) | 2000-02-24 | 2001-09-03 | Philogen S.R.L. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| DE10324447A1 (de) * | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| DE10360483B4 (de) | 2003-12-22 | 2007-11-15 | Scil Proteins Gmbh | Expressionsvektor und dessen Verwendung |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| CA2607954A1 (en) | 2005-05-11 | 2006-11-16 | Philogen S.P.A. | Conjugate for targeting of drug |
| ATE463512T1 (de) | 2005-11-09 | 2010-04-15 | Morphosys Ag | Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern |
| EP1842553A1 (en) | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
| CA2648484A1 (en) | 2006-05-08 | 2007-11-15 | Philogen Spa | Antibody-targeted cytokines for therapy |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| AU2009233925B2 (en) * | 2006-12-05 | 2014-03-13 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| RU2553333C2 (ru) * | 2009-12-14 | 2015-06-10 | Сцил Протеинс Гмбх | Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами |
-
2011
- 2011-06-15 WO PCT/EP2011/002962 patent/WO2012171541A1/en not_active Ceased
-
2012
- 2012-06-15 US US14/126,341 patent/US20140219959A1/en not_active Abandoned
- 2012-06-15 WO PCT/EP2012/061459 patent/WO2012172058A1/en not_active Ceased
- 2012-06-15 AU AU2012268973A patent/AU2012268973A1/en not_active Abandoned
- 2012-06-15 JP JP2014515209A patent/JP2014523238A/ja active Pending
- 2012-06-15 CA CA2837875A patent/CA2837875A1/en not_active Abandoned
-
2013
- 2013-11-28 IL IL229723A patent/IL229723A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523238A5 (https=) | ||
| Walter | The role of structure in the biology of interferon signaling | |
| Morales et al. | The antiviral activities of ISG15 | |
| JP2013541335A5 (https=) | ||
| RU2012114662A (ru) | Модифицированные убиквитиновые белки со специфической связывающей активностью для экстрадомена "в" фибронектина | |
| HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
| JP2017160222A5 (https=) | ||
| JP2013513377A5 (https=) | ||
| JP2010536341A5 (https=) | ||
| JP2017018125A5 (https=) | ||
| JP2011525363A5 (https=) | ||
| HRP20130194T1 (hr) | Imunosupresivni polipeptidi i nukleinske kiseline | |
| CN101143894A (zh) | 高效抑制血管生成多肽及其物理化学修饰方法和应用 | |
| RU2011129860A (ru) | Эффективный транспорт в лейкоциты | |
| JP2017529326A5 (https=) | ||
| JP2014526881A5 (https=) | ||
| JP2018528237A5 (https=) | ||
| JP2016508143A5 (https=) | ||
| JP2015511599A5 (https=) | ||
| HRP20120246T1 (hr) | Aktivne varijante il-18 vezujućeg proteina i njihove medicinske upotrebe | |
| JP2005523681A5 (https=) | ||
| JP2023504826A5 (https=) | ||
| RU2013111675A (ru) | Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc | |
| CN102863537A (zh) | 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用 | |
| KR20240046248A (ko) | 이중특이성 항체 및 이의 응용 |